Liver Fatty Acid-binding Protein as a Sensitive Serum Marker of Acute Hepatocellular Damage in Liver Transplant Recipients

Pelsers, Maurice M.A.L.; Morovat, Alireza; Alexander, Graeme; Hermens, Wim Th.; Trull, Andrew K.; Glatz, Jan F. C.

doi:10.1093/clinchem/48.11.2055

Cited by 64 publications

(55 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatocyte damage results in FABP1 detection in blood (27) and has been proposed as a sensitive serum marker of hepatocellular damage in LT recipients. (28) Recently, FABP1 has been shown to be a diagnostic marker of liver injury in patients with hepatitis C infection (29) and to be associated with drug-induced liver injury. (30) However, to date FABP1 has not been evaluated as a prognostic marker in these conditions or ALF.…”

Section: Comparison With the Literaturementioning

confidence: 99%

“…(27) Furthermore, alphaglutathione S-transferase has also been proposed as a potential biomarker of hepatocyte damage; however, its larger size (26 kDa) and relatively higher expression in kidney and intestine reduce its sensitivity and specificity. (28) Due to its low molecular mass, FABP1 levels in the serum are influenced by both renal function and RRT. FABP1 is present in significantly smaller quantities in the kidney (proximal tubules).…”

Section: Comparison With the Literaturementioning

confidence: 99%

See 1 more Smart Citation

Elevated FABP1 serum levels are associated with poorer survival in acetaminophen‐induced acute liver failure

et al. 2017

View full text Add to dashboard Cite

Background/Aim Acetaminophen (APAP)-induced Acute Liver Failure (ALF) is associated with significant mortality. Traditional prognostic scores lack sensitivity. Hypothesis: Serum Liver-type Fatty Acid Binding Protein (FABP1) early (day 1) or late (day 3–5) levels are associated with 21-day mortality in the absence of liver transplant. Methods Serum samples from 198 APAP-ALF patients (nested case control study with 99 survivors, 99 non-survivors) were analyzed by ELISA methods and assessed with clinical data from the US Acute Liver Failure Study Group (ALFSG) Registry (1998–2014). Results APAP-ALF survivors had significantly lower serum FABP1 levels early (238.6 vs. 690.8 ng/ml, p <0.0001) and late (148.4 vs. 612.3 ng/ml, p <0.0001) compared with non-survivors. FABP1 > 350 ng/ml was associated with significantly higher risk of death at early (p=0.0004) and late (p<0.0001) time points. Increased serum FABP1 early (log FABP1 odds ratio (OR) 1.31, p=0.027) and late (log FABP1 OR 1.50, p =0.005) were associated with significantly increased 21-day mortality after adjusting for significant covariates (MELD, vasopressor use). Areas under the receiver-operating curve (AUROC) for early and late multivariable models were 0.778 and 0.907 respectively. AUROC of the King’s College Criteria (KCC) (Early: 0.552 alone, 0.711 with FABP1; Late: 0.604 alone, 0.797 with FABP1) and ALFSG prognostic index (Early: 0.686 alone, 0.766 with FABP1; Late: 0.711 alone, 0.815 with FABP1) significantly improved with the addition of FABP1 (p <0.002 for all). Conclusion In patients with APAP-ALF, FABP1 may have good potential to discriminate survivors from non-survivors and may improve models currently used in clinical practice. Validation of FABP1 as a clinical prediction tool in APAP-ALF warrants further investigation.

show abstract

Section: Comparison With the Literaturementioning

confidence: 99%

Section: Comparison With the Literaturementioning

confidence: 99%

Elevated FABP1 serum levels are associated with poorer survival in acetaminophen‐induced acute liver failure

et al. 2017

View full text Add to dashboard Cite

show abstract

“…ALAT levels peaked on the first post-operative day, at the same time and in the same range as reported by other groups (19,20), whereas L-FABP levels reached their maximum values at the end of surgery and rapidly decreased thereafter. This might be a reflection of the fact that L-FABP is a more direct and sensitive marker for the detection of liver cell damage as compared with ALAT, because of the small molecular mass and short half-life of L-FABP (16,17,21).…”

Section: Discussionmentioning

confidence: 99%

“…The extent of hepatocellular damage was assessed by plasma concentrations of L-FABP and aminotransferases. L-FABP is a sensitive marker for the detection of liver cell damage (16,17). L-FABP levels were determined using a commercially available ELISA (Hycult Biotechnology, Uden, the Netherlands).…”

Section: Hepatocellular Damagementioning

confidence: 99%

Liver manipulation during liver surgery in humans is associated with hepatocellular damage and hepatic inflammation

Broek

Shiri-Sverdlov

Schreurs

et al. 2013

Liver International

View full text Add to dashboard Cite

show abstract

“…Thus, after acute myocardial infarction, H-FABP was released into the plasma of patients, where it was detected 1.5 h after injury [13]. Intestinal-type (I-) FABP in serum was shown to serve as a marker for small intestine allograft rejection [14], and L-FABP was reported to be a marker in serum for acute hepatocellular damage in liver transplantation [15].…”

Section: Introductionmentioning

confidence: 99%

Expression of liver‐type fatty acid‐binding protein in murine lung and its release into serum upon challenge of lung with lipopolysaccharide

Piumngam

Owada

Kondo

et al. 2005

Eur. J. Lipid Sci. Technol.

View full text Add to dashboard Cite

Expression of liver-type fatty acid-binding protein in murine lung and its release into serum upon challenge of lung with lipopolysaccharideFatty acid-binding proteins (FABP) in alveolar type II (TII) cells are required for surfactant synthesis and regulation. Beyond expression of heart-type (H-) and epidermaltype (E-) FABP in TII cells from mouse lung, we present the first evidence of the expression of liver-type (L-) FABP, by quantitative PCR and immunofluorescent confocal laser microscopy. Further, by making use of an acute mouse lung injury model, we examine whether these lipid-binding proteins are released into the bronchoalveolar fluid (BALF) and into the circulation upon challenge of the lung with lipopolysaccharide. Applying FABP-specific ELISAs, we found that neither H-nor E-FABP can be detected in BALF and serum above background levels, up to 24 h after insult. In contrast, L-FABP was detected in the BALF pellet, consisting of polymorphonuclear cells and alveolar macrophages, and in serum. A significant decrease in L-FABP levels in the BALF pellet was associated with a significant increase in serum levels 6 h post insult. As contributions of L-FABP from other organs were excluded, this protein could be used as a marker for acute lung injury.

show abstract

Liver Fatty Acid-binding Protein as a Sensitive Serum Marker of Acute Hepatocellular Damage in Liver Transplant Recipients

Cited by 64 publications

References 14 publications

Elevated FABP1 serum levels are associated with poorer survival in acetaminophen‐induced acute liver failure

Elevated FABP1 serum levels are associated with poorer survival in acetaminophen‐induced acute liver failure

Liver manipulation during liver surgery in humans is associated with hepatocellular damage and hepatic inflammation

Expression of liver‐type fatty acid‐binding protein in murine lung and its release into serum upon challenge of lung with lipopolysaccharide

Contact Info

Product

Resources

About